利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

79 条记录 (耗时 0.041 秒)

    Humanized antibodies
    12.
    发明授权
    Humanized antibodies 失效
    人源化抗体

    公开(公告)号：US06423511B1

    公开(公告)日：2002-07-23

    申请号：US09393385

    申请日：1999-09-10

    申请人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    发明人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    IPC分类号： C12P2104

    CPC分类号： C07K16/3084 ,  A61K38/00 ,  C07K16/18 ,  C07K16/464 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  Y10S530/867

    摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

    摘要翻译： 通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体， 含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。 将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。 与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期 例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

    DNA encoding humanized antibodies specific for the ganglioside GM.sub.2
    13.
    发明授权
    DNA encoding humanized antibodies specific for the ganglioside GM.sub.2 失效
    编码针对神经节苷脂GM2的人源化抗体的DNA

    公开(公告)号：US5874255A

    公开(公告)日：1999-02-23

    申请号：US438562

    申请日：1995-05-10

    申请人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    发明人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    IPC分类号： A61K38/00 ,  C07K16/18 ,  C07K16/46 ,  C12N1/21 ,  C12N15/13 ,  C12P21/08 ,  C12P21/04 ,  C07H21/04 ,  C12N15/00

    CPC分类号： C07K16/3084 ,  C07K16/18 ,  C07K16/464 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  C07K2319/035 ,  Y10S530/867

    摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

    摘要翻译： 通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体， 含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。 将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。 与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期 例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

    Recombinant antibody against human insulin-like growth factor
    18.
    发明授权
    Recombinant antibody against human insulin-like growth factor 有权
    针对人胰岛素样生长因子的重组抗体

    公开(公告)号：US07498415B2

    公开(公告)日：2009-03-03

    申请号：US10573378

    申请日：2004-09-24

    申请人： Kenya Shitara ,  Kazuyasu Nakamura ,  Yuji Ohki

    发明人： Kenya Shitara ,  Kazuyasu Nakamura ,  Yuji Ohki

    IPC分类号： C07K16/00 ,  C07K16/28

    CPC分类号： C07K16/2896 ,  C07K2317/73

    摘要： It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions.The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter referred to as hIGF-I) and human insulin-like growth factor-II (hereinafter referred to as hIGF-II) to inhibit the biological activities of human IGF-I and human IGF-II, a transformant producing the antibody or the antibody fragment thereof, a process for producing the antibody or the antibody fragment thereof, and a medicament comprising the antibody or the antibody fragment thereof as the active ingredient therein.

    摘要翻译： 要求用于治疗治疗诸如癌症，肢端肥大症和糖尿病并发症的药剂，其中IGF涉及条件的进展。 本发明提供与人胰岛素样生长因子-1（以下称为hIGF-1）和人胰岛素样生长因子-II（以下称为hIGF-II）特异性结合的重组抗体或其抗体片段 ）抑制人IGF-I和人IGF-II的生物活性，产生抗体或其抗体片段的转化体，制备抗体或其抗体片段的方法，以及包含抗体或抗体片段的药物 作为其中的活性成分。

    Antibody against human insulin-like growth factor
    19.
    发明授权
    Antibody against human insulin-like growth factor 有权
    抗人类胰岛素样生长因子的抗体

    公开(公告)号：US07438911B2

    公开(公告)日：2008-10-21

    申请号：US10513148

    申请日：2003-04-30

    申请人： Kenya Shitara ,  Kazuyasu Nakamura ,  Akiko Furuya ,  Rinpei Niwa ,  Yuji Ohki ,  Nobuo Hanai

    发明人： Kenya Shitara ,  Kazuyasu Nakamura ,  Akiko Furuya ,  Rinpei Niwa ,  Yuji Ohki ,  Nobuo Hanai

    IPC分类号： A61K39/395 ,  G01N33/53 ,  C12N5/06 ,  C12N15/00 ,  C12P21/08 ,  C07K16/22

    CPC分类号： C07K16/22 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5×109 M−1 or more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.

    摘要翻译： 为了有效治疗诸如hIGF参与的癌症的疾病，期望开发出与hIGF-1和hIGF-II两者强烈结合并抑制其功能和这些抗体片段的抗体。 本发明提供具有特异性结合人IGF-I和IGF-II从而抑制人IGF-I和IGF-II的功能并具有结合常数为5×10 9的结合活性的抗体， 或者用生物传感器BIACORE测量的更高/更高。 此外，本发明提供了hIGF介导的疾病的诊断，预防措施和补救措施以及由于异常促进的hIGF产生导致使用所述抗体的病理进展的疾病。